EUCTR2008-001405-41-DE进行中（未招募）不适用
A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX) - LEOMEX
GMIHO mbH0 个研究点开始时间: 2008年8月28日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Untreated patients with systemic AL amyloidosis
- •-Age between 18 and 74 years
- •-Not eligible for or refused high-dose chemotherapy
- •-NYHA stage < IV
- •-Measurable plasma cell disorder
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Multiple myeloma stage II and III
- •-Not able to visit the Amyloidosis Clinic in Heidelberg once per months
- •-Pregnant or breast feeding females
- •-Not able to give informed consent
研究者
相似试验
进行中（未招募）
不适用
Phase I/II Trial of Lenalidomide in Combination with Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients with Peripheral T-Cell Non-Hodgkin’s Lymphoma (PTCL)EUCTR2008-006919-20-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
进行中（未招募）
不适用
A Phase 1/2 Study of Lenalidomide in combination with Bendamustine (LEBEN) in relapsed and primary refractory Hodgkin Lymphomarelapsed and primary refractory Hodgkin LymphomaMedDRA version: 14.1Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002810-35-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
进行中（未招募）
不适用
A Phase I/II trial of lenalidomide combined with cyclophosphamide and intermediate dose dexamethasone in patients with primary (AL) systemic amyloidosis - CDR in amyloidosisEUCTR2006-007082-36-GRHellenic Oncology Cooperative Group55
进行中（未招募）
1 期
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple MyelomaAsymptomatic High-Risk Smoldering Multiple MyelomaMedDRA version: 18.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2012-000750-66-IEICORG-the All Ireland Co-operative Oncology Research Group40
进行中（未招募）
1 期
Randomized phase II Trial comparing Lenalidomide with lowdose dexamethasone versus Lenalidomide inSecond Line Multiple Myeloma (MM)Multiple myelomaMedDRA version: 16.1Level: LLTClassification code 10028231Term: Multiple myeloma in remissionSystem Organ Class: 100000004864MedDRA version: 16.1Level: LLTClassification code 10028233Term: Multiple myeloma without mention of remissionSystem Organ Class: 100000004864MedDRA version: 16.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2010-021857-38-SEKarolinska University Hospital60